本文選題：匹多莫德 + 阿維A膠囊　； 參考：《臨床醫(yī)學(xué)》2016年11期

【摘要】：目的探討匹多莫德聯(lián)合阿維A膠囊治療復(fù)發(fā)性尖銳濕疣(CA)人乳頭瘤病毒(HPV)亞型的應(yīng)用價(jià)值。方法以隨機(jī)數(shù)字表法將66例復(fù)發(fā)性CA HPV亞型患者分為兩組,每組33例。以接受二氧化碳激光治療者為對(duì)照組,以在接受二氧化碳激光治療同時(shí)聯(lián)合應(yīng)用匹多莫德及阿維A膠囊治療者為觀察組。對(duì)比兩組治療前后T淋巴細(xì)胞亞群變化情況及臨床治療效果。結(jié)果兩組間入組時(shí)DLQI評(píng)分、SCL-90評(píng)分、CD_3~+、CD_4~+、CD8+百分比及CD_4~+/CD8+比較差異未見統(tǒng)計(jì)學(xué)意義(P0.05);而在接受治療3個(gè)月后,觀察組DLQI評(píng)分及CD8+百分比低于對(duì)照組,SCL-90評(píng)分、CD_3~+、CD_4~+百分比及CD_4~+/CD8+高于對(duì)照組(P0.05)。觀察組治療總有效率明顯高于對(duì)照組(P0.05)。觀察組治療不良反應(yīng)發(fā)生率明顯低于對(duì)照組(P0.05)。結(jié)論匹多莫德聯(lián)合阿維A膠囊治療可有效改善復(fù)發(fā)性CA HPV亞型免疫指標(biāo),并可在有效的提高治療效果的同時(shí),顯著的降低不良反應(yīng)發(fā)生率。
[Abstract]:Objective to evaluate the clinical value of pidomod combined with avea capsule in the treatment of recurrent condyloma acuminatum (CA) human papillomavirus (HPV) subtype. Methods 66 patients with recurrent CA HPV subtype were randomly divided into two groups, 33 cases in each group. The control group was treated with carbon dioxide laser and those who were treated by carbon dioxide laser combined with pidomod and avea capsule as the observation group. The changes of T lymphocyte subsets before and after treatment were compared between the two groups. Results there was no significant difference in DLQI score, SCL-90 score, CD3 ~ + CD4 ~ / CD8% and CD4 ~ / CD8 between the two groups (P0.05), but after 3 months of treatment, there was no significant difference in the percentage of CD3 / CD8 and CD4 / CD8 between the two groups (P0.05), but after 3 months of treatment, there was no significant difference between the two groups. The DLQI score and CD8 percentage in the observation group were lower than those in the control group. The percentage of CD3 / CD8 and CD4 / CD8 were significantly higher in the observation group than in the control group (P0.05). The total effective rate in the observation group was significantly higher than that in the control group (P0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P0.05). Conclusion Pidomod combined with avea capsule can effectively improve the immune index of recurrent CA HPV subtype and decrease the incidence of adverse reactions.
【作者單位】： 廣東省鶴山市人民醫(yī)院;廣州市第一人民醫(yī)院;
【分類號(hào)】：R752.53
，

本文編號(hào)：2076114